BioNTech Results Presentation Deck
BNT162b2 Boosters to Address Partial Immune Escape by Omicron
Israel real-world data suggest a 4th dose increases
immunogenicity and lowers rates of confirmed
infections and severe illness in elderly population ⁹
BNT162b2 3rd dose required to reinstall immunity
and effectiveness against Omicron ¹
14
●
●
Overall infections (~70-80%)¹-4
Symptomatic disease (~50-85%)1-5
Hospitalizations (~75-90%)2-6
However: Vaccine effectiveness against Omicron starts
waning after the first few months post booster7,8
●
Monitoring of emerging variants
In subjects >60 years of age, confirmed infection and severe
disease after 4th dose¹ was lower compared to individuals who did
not receive 4th dose⁹
At 12 days+ post 4th dose, reduced risk was demonstrated
compared to only 3 doses 9:
Infection by a factor of 2.0
(95% CI 2.0 to 2.1)
Severe disease by a factor of 4.3
(95% CI 2.2 to 7.5)
Future pandemic preparedness:
Rapid data-guided vaccine adaptation
1 Collie SH, et al. N Engl J Med 2022; 386:494-496 DOI: 10.1056/NEJMC2119270; 2 UK Health Security Agency. COVID-19 Vaccine Surveillance Report - Week 8. 24 February 2022; 3 Tartof SY, et al. Available at
SSRN: https://ssrn.com/abstract=4011905; 4 Hansen CH, et al. MedRXiv. doi: https://doi.org/10.1101/2021.12.20.21267966; 5 Thompson MG, et al. MMWR Morb Mortal Wkly Rep 2022;71:139-145.
DOI: http://dx.doi.org/10.15585/mmwr.mm 7104e3external icon; 6 Lauring AS, et al. BMJ 2022; 376 doi: https://doi.org/10.1136/bmj-2021-069761; 7 Andrews N, et al. NEJM 2022. DOI: 10.1056/NEJMoa2119451;
8 Ferdinands JM, et al. MMWR Morb Mortal Wkly Rep 2022;71:255-263. DOI: http://dx.doi.org/10.15585/mmwr.mm 7107e2external icon;
9 Bar-On YM, et al MedRxiv [Preprint] https://doi.org/10.1101/2022.02.01.22270232.
BIONTECHView entire presentation